ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2024 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided EPS guidance of 4.900-5.050 for the period, compared to the consensus EPS estimate of 4.720. The company issued revenue guidance of $594.0 million-$602.0 million, compared to the consensus revenue estimate of $590.3 million.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ANIP shares. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Finally, Raymond James lifted their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $58.38 on Friday. The company’s 50-day moving average price is $58.70 and its two-hundred day moving average price is $61.58. The firm has a market cap of $1.23 billion, a P/E ratio of 49.90 and a beta of 0.71. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. The business had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm’s quarterly revenue was up 18.5% compared to the same quarter last year. During the same period last year, the firm posted $1.06 earnings per share. On average, analysts anticipate that ANI Pharmaceuticals will post 3.5 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.